NCT01136863

Felodipine Event Reduction Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 9,800 (actual)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 50 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

FEVER is an investigator-designed, prospective, multicentre,double-bind, randomized, placebo-controlled,parallel-group trial. The primary objective is to compare the long-term effects on the incidence of fatal and non-fatal stroke (and secondarily of other cardiovascular events) of administering a small dose of the calcium antagonist felodipine (5 mg once a day) or of a placebo, in hypertensive patients whose blood pressure had preliminarily been reduced by administering a low-dose diuretic (hydrochlorothiazide,12.5 mg once a day) to be continued in association with felodipine or placebo, throughout the trial.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Felodipine
DRUG	Placebo

Timeline

• Start date: 1998-04-01
• Primary completion: 2004-06-01
• Completion: 2004-06-01
• First posted: 2010-06-04
• Last updated: 2010-06-25

Locations

1 site across 1 country: China